Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea

BACKGROUND: The anti-CD20 monoclonal antibody rituximab (RTX) has been proposed as a rescue therapy for difficult-to-treat nephrotic syndrome (NS). We conducted a clinical trial to evaluate the efficacy and safety of RTX in children with difficult-to-treat NS dependent on or resistant to steroids an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Yo Han, Kim, Seong Heon, Han, Kyoung Hee, Choi, Hyun Jin, Cho, Heeyeon, Lee, Jung Won, Shin, Jae Il, Cho, Min Hyun, Lee, Joo Hoon, Park, Young Seo, Ha, Il-Soo, Cheong, Hae Il, Kim, Su Young, Lee, Seung Joo, Kang, Hee Gyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257685/
https://www.ncbi.nlm.nih.gov/pubmed/30431588
http://dx.doi.org/10.1097/MD.0000000000013157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257685/
https://www.ncbi.nlm.nih.gov/pubmed/30431588
http://dx.doi.org/10.1097/MD.0000000000013157

Ejemplares similares